Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HBB | P68871 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320491 | 0.87 | ALDH1A1 (0.48) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL156784 | 0.87 | ATAD2 (0.48) | ATAD2 | |
| SCHEMBL7074433 | 0.87 | LMNA (0.43) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL7070324 | 0.87 | GAA (0.50) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL5800398 | 0.85 | — | — | |
| SCHEMBL356483 | 0.83 | TYMP (0.49) | ATAD2 | |
| SCHEMBL7599681 | 0.83 | ALDH1A1 (0.45) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL161148 | 0.83 | ATAD2 (0.54) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL7603360 | 0.82 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| SCHEMBL30464746 | 0.82 | CYP3A4 (0.49) | DPYD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318987-A1 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | claimed |
| EP-2124919-A2 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080318987-A1 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
| WO-2008103314-A2 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318987-A1 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | BMP4, BMP2, SOST | DPYD 3965/4885GAA 2152/4885ATAD2 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.